NC-KBI-BIOPHARMA
1.4.2024 13:58:27 CEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401053397/en/
Peter Carbone, KBI Biopharma Chief Quality Officer (Photo: Business Wire)
A highly respected and successful industry leader, Peter brings over 35 years of experience in operations, quality, and technology leadership in a diverse range of areas in the life sciences spectrum, including biotechnology, pharmaceuticals, and advanced therapies. Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
"We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D. Mowery, President & CEO of KBI Biopharma. "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers. His passion for making a difference in the world, coupled with his drive to develop and deliver innovative products that improve patients’ lives, makes him an invaluable asset to KBI.”
“I am thrilled to join KBI Biopharma during a time of significant evolution for the company,” said Peter Carbone, Chief Quality Officer of KBI Biopharma. “We are poised for remarkable advancements in the biopharma industry, and I look forward to working with this talented team to drive innovation, ensure quality, deliver exceptional results, and ultimately make a meaningful impact on patients’ lives worldwide.”
Prior to joining KBI, Peter led engineering, operations, and quality organizations at major pharmaceutical companies, including Bayer, Amgen, Allergan, Novartis, Acorda, and the Center of Breakthrough Medicines. He holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401053397/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 08:05:00 CET | Press release
Planned data center campus in Skellefteå would support future AI and cloud infrastructure needs EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to r
Lyten Completes Acquisition of Northvolt Sweden and Establishes its First Lyten Industrial Hub in Sweden27.2.2026 08:00:00 CET | Press release
Lyten announces it has completed the acquisition of Northvolt’s battery assets in Sweden, totaling nearly $5B in value.The Skellefteå battery site, Northvolt Ett, is resuming operations and plans to deliver commercial cells in 2H 2026.Lyten announces the establishment of the Lyten Industrial Hub in Skellefteå, Sweden to co-locate battery manufacturing, data centers, and additional manufacturing activities.In connection with the closing, EdgeConneX, a portfolio company of EQT, plans to acquire a data center site from Lyten, with potential capacity of up to one gigawatt. Lyten, a global leader in lithium-sulfur batteries and energy storage, announced today that it has completed the acquisition of Northvolt Ett and Ett Expansion (Skellefteå, Sweden) and Northvolt Labs (Västerås, Sweden). The Northvolt Sweden acquisition includes 16 GWh of existing battery manufacturing capacity, more than 160 hectares of land, infrastructure and buildings to support expanded manufacturing and industrial a
SOLUM and Competera Expand Partnership to Integrate AI-Driven Pricing Solutions with Real-Time ESL Execution Across Europe27.2.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Competera announced the expansion of their strategic partnership to further connect AI-driven pricing intelligence with real-time Electronic Shelf Label (ESL) execution across European retail networks. The announcement follows strong engagement at EuroShop, where the integrated solution attracted significant interest from the local retail operators. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226065052/en/ SOLUM and Competera announced the expansion of their strategic partnership (Image: SOLUM) The collaboration brings together Competera’s AI-driven pricing solutions for enterprise retail with SOLUM’s Newton ESL platform, enabling retailers to align advanced price optimization with synchronized shelf-edge communication. Competera’s platform applies machine learning and advanced analytics to help retailers balance competitiveness and value-based pricing, strengthen customer loyalty, improve pri
OpenSynergy's Blue SDK Now Drives More Than 400 Million Cars27.2.2026 08:00:00 CET | Press release
OpenSynergy's Blue SDK, the industry-leading independent Bluetooth® stack, is now deployed in over 400 million cars. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226654887/en/ OpenSynergy's Blue SDK now drives more than 400 million cars OpenSynergy is thrilled and very proud to announce that Blue SDK is now integrated in more than an estimated 400 million cars worldwide, deployed by virtually all the major OEMs across a wide range of vehicles, segments, and markets, offering extensive and consistent interoperability between many generations of smartphones and cars. “This is an incredible milestone for OpenSynergy, but it is also a testament to the ubiquity of the Bluetooth standard in our everyday lives and the success of the entire Bluetooth ecosystem under the leadership of the Bluetooth SIG,” comments Kathleen Ende, CEO, OpenSynergy. “Blue SDK is now an essential part of the daily automotivecockpit plug and play expe
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27.2.2026 07:00:00 CET | Press release
Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1 Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5 Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom